- Home
- FCAP vs EVMN Comparison
FCAP vs EVMN Comparison
Compare FCAP & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FCAP | EVMN |
|---|---|---|
| Founded | 1891 | 2020 |
| Country | United States | United States |
| Employees | N/A | 48 |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 215.1M | 185.1M |
| IPO Year | 1998 | 2025 |
Fundamental Metrics
Financial Performance| Metric | FCAP | EVMN |
|---|---|---|
| Price | $62.55 | $5.11 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $22.33 |
| AVG Volume (30 Days) | 15.0K | ★ 780.3K |
| Earning Date | 11-03-2026 | 11-07-2026 |
| Dividend Yield | ★ 2.00% | N/A |
| EPS Growth | 36.97 | ★ 75.23 |
| EPS | ★ 2.72 | N/A |
| Revenue | $7,170,000.00 | ★ $13,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.47 | ★ N/A |
| Revenue Growth | 1.57 | ★ 85.71 |
| 52 Week Low | $41.63 | $5.09 |
| 52 Week High | $71.00 | $33.20 |
Technical Indicators
Market Signals| Indicator | FCAP | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 54.61 | 20.59 |
| Support Level | $62.07 | N/A |
| Resistance Level | $64.43 | $13.35 |
| Average True Range (ATR) | 1.77 | 0.36 |
| MACD | 0.08 | 0.08 |
| Stochastic Oscillator | 60.98 | 10.69 |
Price Performance
Historical ComparisonAbout FCAP First Capital Inc.
First Capital Inc is an Indiana chartered commercial bank that provides a variety of banking services to individuals and businesses. It provides retail and business banking, residential mortgage lending, real estate finance, and asset-based lending. The bank's primary source of revenue is real estate mortgage loans.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.